Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Promise of GPRC5D-targeted CAR-T therapies in multiple myeloma

Adam Sperling • 4 Jun 2023
ASCO 2023
Multiple Myeloma CAR-T

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, talks on targets for CAR-T and cellular therapies in multiple myeloma, including BCMA, and GPRC5D, and highlights the potential of rapid manufacturing approaches in other non-BCMA-targeting cellular therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Adam Sperling

1:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling • 27 Sep 2023
1:58
Clonal hematopoiesis in multiple myeloma and implications for therapy
Adam Sperling • 27 Sep 2023
2:05
Novel CAR-T constructs being explored in myeloma: T-Charge platform
Adam Sperling • 27 Sep 2023
1:53
PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myeloma
Adam Sperling • 4 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals